Candidiasis market is estimated to be valued at USD 1,307.2 Mn in 2026 and is expected to reach USD 1,790.7 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 4.6% from 2026 to 2033.
The growth of the candidiasis market is supported by increasing prevalence of fungal infections, increase in rates of diabetes and HIV/AIDS infection, increase in use of broad-spectrum antibiotics and rise in awareness about early diagnosis & treatment. The growth of the market is driven by increasing awareness about antifungal therapies, emerging technologies for diagnostics and rising healthcare expenditure. However, global burden of antifungal resistant Candida species, recurrence after treatment and high costs of newer therapy are significant hurdles. Meanwhile, opportunities are emerging by developing new antifungal agents, improved access to generic medicines and increased investment in rapid diagnostics.
Based on Drug Class, Azoles segment is anticipated to capture more than 42.7% of the market as compared to others in 2026. Its broad-spectrum antifungal activity, low cost, ease of oral formulations delivery and use as the first-line treatment for superficial and systemic candidiasis infections give it leadership in this segment.
On the basis of Type, Vaginal Candidiasis is expected to hold a share of around 36.0% in the year 2026. This segment’s growth is propelled by its high prevalence across the globe, frequent recurrence in females, easy accessibility of over-the-counter antifungal drugs along with growing consciousness related to women health and early intervention.
Based on Route of Administration, the Oral segment is anticipated to account for a large market share in 2026, approximately 50.0%, due to simplicity of administration, convenience for patients and low-grade resources availability with price levels manageable by healthcare systems followed by a wide availability of oral antifungal therapies available both prophylactically and therapeutically.
On the basis of Distribution Channel, the Hospital Pharmacies segment is anticipated to control a share of about 45.0% in 2026 as extensive cases of severe and invasive candidiasis need expert antifungal treatments and institutional care.
By region, North America is estimated to lead the candidiasis market throughout 2026 with an approximate of 41.0% market share due to the presence of a developed healthcare infrastructure coupled with high cases of fungal infections among immunocompromised patients, and supportive reimbursement policies as well as a long track record of antifungal therapy innovations in this region. Asia Pacific is expected to be the fastest-growing region due to increasing incidence rates of fungal infections, improving healthcare infrastructure, low-cost availability of generic antifungal drugs, rising awareness regarding diagnosis and treatment along with increasing investment in healthcare systems by countries like China and India.
Prominent Players in the Candidiasis Market
-
Basilea Pharmaceutica Ltd.
Company Overview
- Headquarters: Allschwil, Switzerland
- Establishment Year: 2000
- Employee Strength: Approximately 150 employees
- Leadership: Mr. David Veitch, Chief Executive Officer
- Core Services/Products: Antifungal therapeutics, antibacterial medicines, oncology drug development, infectious disease treatments, and pharmaceutical research. Key antifungal products include Cresemba (isavuconazole).
SWOT Analysis
- Strengths
- Extensive experience in antifungal and anti-infective drug development.
- Cresemba for invasive fungal infections; commercial presence established.
- Weaknesses
- Different product pipeline as compared to big pharmaceutical industries.
- A very high dependency on revenues from partners and licensing.
- Opportunities
- Increased need for new antifungal treatments against resistant strains of Candida
- Expanding into emerging channels through partnerships.
